Michael S. Gordon

Translational Genomics Research Institute — United States

Medicine · Health Sciences

72h-index27.8kcitations573works8.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(107), CAR-T cell therapy research(55), Colorectal Cancer Treatments and Studies(50), Cancer Treatment and Pharmacology(39), Renal cell carcinoma treatment(37)

Publications554 total

Phase IB trial of high dose ascorbic acid + nab-paclitaxel + cisplatin + gemcitabine in patients with untreated metastatic pancreatic cancer
Redox Biology·2025Open Access
Everolimus and Low-Dose Tacrolimus After Heart Transplant in Children
JAMA·2025· 1 citedOpen Access
8P Botensilimab plus balstilimab in an expanded cohort of 123 patients with metastatic microsatellite-stable colorectal cancer and no active liver metastases
Annals of Oncology·2025· 2 citedOpen Access
An open-label, phase 1 trial with expansion cohort of botensilimab (AGEN1181) + balstilimab (AGEN2034) + nab-paclitaxel + gemcitabine + cisplatin + chloroquine + celecoxib in adult patients with previously untreated metastatic pancreatic cancer.
Journal of Clinical Oncology·2025
An open-label phase 1/2 study of DCC-3009 monotherapy in patients with advanced gastrointestinal stromal tumor.
Journal of Clinical Oncology·2025
A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer
ESMO Open·2025· 37 citedOpen Access
Non‐Mosaic Trisomy 9: Further Delineation of the Clinical Phenotype
American Journal of Medical Genetics Part A·2025
Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer
Journal for ImmunoTherapy of Cancer·2025· 10 citedOpen Access
Botensilimab (Fc-enhanced anti–cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti–PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas
Journal of Clinical Oncology·2025· 15 citedOpen Access
Physical, biochemical, and biological characterization of olive-derived lipid nanovesicles for drug delivery applications
Journal of Nanobiotechnology·2024· 13 citedOpen Access
Abstract A002: Phase II Trial of Vemurafenib + Sorafenib in Advanced KRAS Mutated Pancreas Cancer
Cancer Research·2024
1690O NKT2152, a novel oral HIF-2α inhibitor, in participants (pts) with previously treated advanced clear cell renal carcinoma (accRCC): Preliminary results of a phase I/II study
Annals of Oncology·2024· 8 citedOpen Access
1726MO Updated efficacy and safety of botensilimab plus balstilimab in patients with refractory metastatic sarcoma from an expanded phase I study
Annals of Oncology·2024· 1 cited
Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial
Nature Medicine·2024· 80 citedOpen Access
CO22 Health-Related Quality of Life from a Phase 4 Global Clinical Study to Evaluate Discontinuation and Rechallenge of Pexidartinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) Previously Treated with Pexidartinib
Value in Health·2024Open Access
Phase <scp>II</scp> clinical trial of nab‐paclitaxel plus cisplatin plus gemcitabine (<scp>NABPLAGEM</scp>) in patients with untreated advanced pancreatic cancer
Cancer Medicine·2024· 5 citedOpen Access
Final outcomes analysis of the cell product SQZ‐PBMC‐HPV Phase 1 trial in incurable HPV16+ solid tumors shows improved overall survival in patients with increased CD8+ T cell tumor infiltration
Molecular Carcinogenesis·2024· 5 citedOpen Access
Abstract 4107: Evaluating the efficacy of personalized neoantigen cancer vaccine in preclinical model: A promising step towards precision immunotherapy
Cancer Research·2024
58MO Evaluation of three pexidartinib doses in a global phase IV clinical study of patients with tenosynovial giant cell tumor (TGCT) who chose to continue treatment
ESMO Open·2024Open Access
Paclitaxel protein bound (A) plus gemcitabine (G) plus cisplatin (C) and hydroxychloroquine (HCQ) neoadjuvant therapy for localized pancreatic ductal adenocarcinoma (PDAC).
Journal of Clinical Oncology·2024
page 1 of 28Next →

Frequent Co-authors

David S. Mendelson(7), Michael B. Atkins(5), Jeffrey R. Infante(5), Razelle Kurzrock(5), Roy S. Herbst(4), Omid Hamid(4), Jeffrey A. Sosman(4), Marcella Fassò(4), Manish R. Patel(4), James L. Gulley(4), Howard A. Burris(4), Nicholas J. Vogelzang(4), Gregg Fine(3), David F. McDermott(3), John D. Powderly(3), Ann A. Jakubowski(3), Kim Margolin(3), Joseph I. Clark(3), John W. Smith(3), Leisha A. Emens(3)